Scholarlink

<p>Diabetes mellitus affects over 589&#xa0;million adults globally, with projections exceeding 900&#xa0;million by 2050. Conventional antidiabetic therapies are limited by adverse effects, high cost, and single-target pharmacology. Endophytic microorganisms, fungi and bacteria residing asymptomatically within plant tissues, represent an underexplored yet structurally diverse reservoir of bioactive metabolites developed through co-evolutionary adaptation with their hosts. This scoping review aimed to systematically map the breadth and depth of available evidence on: (1) the antidiabetic biochemical mechanisms of endophyte-derived metabolites; (2) bioprospecting and biotechnological discovery strategies; and (3) key translational barriers to clinical application, to identify research priorities and knowledge gaps. A systematic search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and ScienceDirect covering January 2016 to March 2026, supplemented by hand-searching of reference lists. The Boolean search strategy combined endophyte-specific, antidiabetic, and metabolite-related terms. Studies were screened against explicit inclusion and exclusion criteria following PRISMA for Scoping Reviews (PRISMA-ScR) guidelines. A total of 747 records were identified; following duplicate removal and two-stage screening, 123 studies were included in the final synthesis. Included studies documented seven principal antidiabetic mechanisms of endophyte-derived metabolites: (1) inhibition of α-glucosidase and α-amylase; (2) enhancement of GLUT4 translocation via the IRS1/PI3K/Akt/GSK3β axis; (3) AMPK activation suppressing hepatic gluconeogenesis; (4) PPARγ agonism improving insulin sensitivity; (5) antioxidant protection of pancreatic β-cells from ROS-induced apoptosis; (6) anti-inflammatory modulation of TNF-α, IL-6, and IL-1β via NF-κB/MAPK pathways; and (7) multi-target engagement. Bioprospecting strategies, including OSMAC, genomic mining, co-culture systems, and AI-assisted discovery, are accelerating compound identification. Key translational barriers include inconsistent metabolite yields, strain instability, regulatory complexity, and unresolved intellectual property disputes. Endophytic microorganisms constitute a compelling and sustainable source of multi-target antidiabetic compounds. This review provides the first PRISMA-ScR compliant synthesis of the field, offering clinicians, natural product researchers, pharmaceutical scientists, and policymakers a rigorous evidence base for prioritising endophyte-derived lead compounds for preclinical and clinical development. Substantial knowledge gaps remain in the in vivo validation, clinical translation, and equitable access frameworks for microbial resources from biodiverse regions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Endophytic microorganisms as sustainable sources of antidiabetic metabolites: biochemical mechanisms, bioprospecting strategies, and translational challenges

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Sherif B. Adeyemi,
  • Mercy A. Alabi,
  • Hafizah Y. Chenia,
  • Tricia Lin,
  • Johnson Lin

摘要

Diabetes mellitus affects over 589 million adults globally, with projections exceeding 900 million by 2050. Conventional antidiabetic therapies are limited by adverse effects, high cost, and single-target pharmacology. Endophytic microorganisms, fungi and bacteria residing asymptomatically within plant tissues, represent an underexplored yet structurally diverse reservoir of bioactive metabolites developed through co-evolutionary adaptation with their hosts. This scoping review aimed to systematically map the breadth and depth of available evidence on: (1) the antidiabetic biochemical mechanisms of endophyte-derived metabolites; (2) bioprospecting and biotechnological discovery strategies; and (3) key translational barriers to clinical application, to identify research priorities and knowledge gaps. A systematic search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and ScienceDirect covering January 2016 to March 2026, supplemented by hand-searching of reference lists. The Boolean search strategy combined endophyte-specific, antidiabetic, and metabolite-related terms. Studies were screened against explicit inclusion and exclusion criteria following PRISMA for Scoping Reviews (PRISMA-ScR) guidelines. A total of 747 records were identified; following duplicate removal and two-stage screening, 123 studies were included in the final synthesis. Included studies documented seven principal antidiabetic mechanisms of endophyte-derived metabolites: (1) inhibition of α-glucosidase and α-amylase; (2) enhancement of GLUT4 translocation via the IRS1/PI3K/Akt/GSK3β axis; (3) AMPK activation suppressing hepatic gluconeogenesis; (4) PPARγ agonism improving insulin sensitivity; (5) antioxidant protection of pancreatic β-cells from ROS-induced apoptosis; (6) anti-inflammatory modulation of TNF-α, IL-6, and IL-1β via NF-κB/MAPK pathways; and (7) multi-target engagement. Bioprospecting strategies, including OSMAC, genomic mining, co-culture systems, and AI-assisted discovery, are accelerating compound identification. Key translational barriers include inconsistent metabolite yields, strain instability, regulatory complexity, and unresolved intellectual property disputes. Endophytic microorganisms constitute a compelling and sustainable source of multi-target antidiabetic compounds. This review provides the first PRISMA-ScR compliant synthesis of the field, offering clinicians, natural product researchers, pharmaceutical scientists, and policymakers a rigorous evidence base for prioritising endophyte-derived lead compounds for preclinical and clinical development. Substantial knowledge gaps remain in the in vivo validation, clinical translation, and equitable access frameworks for microbial resources from biodiverse regions.